Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Conflict Of Interest Policy May Be Biggest Conflict Of PDUFA Reauthorization

Feb 06 2012

• By Derrick Gingery

Related Content

Drug Shortage Bills Likely Drivers Of PDUFA Add-ons

Nov 29 2011

Good Neighbors Make Good Regulatory Science Centers, FDA Decides

Nov 28 2011

Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch

Jan 09 2012

PDUFA V: Can FDA Fight Off Mission Creep This Cycle?

Feb 06 2012

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

Jun 03 2011

Burgess Not Changing Conflict Of Interest Thinking Despite Flap Over Oral Contraceptive AC

Jan 23 2012

Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on

Aug 01 2011

PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter

Oct 31 2011

Rx Safety Bill Produces Restless REMS; Core Of “KEnzi” Is Narrowed But Intact

Apr 23 2007

Related Companies

Pfizer Inc.

Alkermes plc

Bayer AG

Vivus, Inc.

Additional Topics

United States Legislation Advisory Committees BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window